Elanco Animal Health CEO: Seeing a willingness to spend, durability even in 'consumer tested' time

Core Insights - Ela Co. Animal Health reported a 9% organic constant currency growth, marking nine consecutive quarters of growth, driven by both pet and livestock segments [1][2] - The company experienced its highest quality quarter of growth in three to four years, attributed to innovation in pet health products and strong demand in the livestock sector [3][4] Pet Segment - Pet owners are increasingly willing to spend on innovative health products, particularly in areas like dermatology and pain management for pets [3] - The company has a significant product, Credelo Quattro, which has rapidly gained traction, becoming the fastest product to reach $100 million in sales [7][8] Livestock Segment - The livestock market is benefiting from high protein demand, with the US beef market experiencing a shortage of cattle at a 50-year low, leading to strong beef economics [4] - The company is focusing on ruminant markets, including dairy, beef, and poultry, as key growth areas [9] Innovation and Product Pipeline - Ela Co. emphasizes innovation as the primary driver of growth, with a diverse portfolio across multiple species and therapeutic classes [6][7] - The company plans to discuss its strategies for the ruminant, poultry, and pet markets during an upcoming investor day [9]